Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
Investor Relations
Latest Financial Results
Q3 2021
Quarterly Results
Ended Sep 30, 2021
Stock Information
Symbol
NYSE American: OGEN
Price
Change
Day Range
52 Wk Range
Company Overview
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Contact Information
Investor Relations
LHA Investor Relations
Kim Golodetz
Senior Vice President, Principal
T: 212-838-3777
kgolodetz@lhai.com
Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000